Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden.
Metrics to compare | ACELP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipACELPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.2x | −2.2x | −0.5x | |
PEG Ratio | −0.10 | −0.04 | 0.00 | |
Price/Book | 4.0x | 2.5x | 2.6x | |
Price / LTM Sales | - | 16.3x | 3.2x | |
Upside (Analyst Target) | 98.8% | 79.2% | 43.6% | |
Fair Value Upside | Unlock | 12.2% | 4.9% | Unlock |